Floatz logo

DARATUMUMAB

Blood Protein Disorders

Hellenic Society of Hematologymonoclonal_antibodyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Blood Protein Disorders cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Hellenic Society of Hematology
Phase 3BB
cc-5013
Hellenic Society of Hematology
Phase 3BB
Pomalidomide
Hellenic Society of Hematology
Phase 2B
Cyclophosphamide
Hellenic Society of Hematology
Phase 2CCC
RANITIDINE
Hellenic Society of Hematology
Phase 2CCC

View all 14 →

Same molecule, other indications

DARATUMUMAB is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
67 / 100
View asset →
smoldering plasma cell myelomaDormant
BB
Indicative ·
65 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →